Document 0271
 DOCN  M94A0271
 TI    Management of systemic manifestations of fungal disease in patients with
       AIDS.
 DT    9412
 AU    Stevens DA; Department of Medicine, Santa Clara Valley Medical Center,
       San; Jose, CA 95128-2699.
 SO    J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S64-7. Unique Identifier :
       AIDSLINE MED/94358253
 AB    In patients with AIDS with cryptococcosis, prompt diagnosis is
       essential. Poor results with conventional therapy (amphotericin-5FC)
       have led to exploration of the azoles. Both fluconazole and itraconazole
       have given good short-term results with less toxicity. However, cure is
       achieved far less often than in other compromised hosts. Fluconazole is
       also useful to prevent relapse after successful initial amphotericin
       therapy, particularly from genitourinary foci. In both histoplasmosis
       and aspergillosis, itraconazole has produced impressive therapeutic
       results, and in histoplasmosis, secondary prophylaxis as well. In
       coccidioidomycosis results thus far have not been better than
       conventional amphotericin therapy, especially in initial treatment.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Amphotericin
       B/*THERAPEUTIC USE  Coccidioidomycosis/COMPLICATIONS/*DRUG
       THERAPY/EPIDEMIOLOGY/  IMMUNOLOGY  Cryptococcosis/COMPLICATIONS/*DRUG
       THERAPY/EPIDEMIOLOGY/  IMMUNOLOGY  Drug Therapy, Combination
       Fluconazole/*THERAPEUTIC USE  Histoplasmosis/COMPLICATIONS/*DRUG
       THERAPY/EPIDEMIOLOGY/  IMMUNOLOGY  Human  Itraconazole/*THERAPEUTIC USE
       Meningitis, Cryptococcal/COMPLICATIONS/DRUG THERAPY/EPIDEMIOLOGY/
       IMMUNOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).